CRNX insider sale: 6,492 shares sold at $29.18 VWAP

Q: What did Dana Pizzuti (CRNX) report on Form 4?

She reported selling 6,492 shares of Crinetics common stock on 08/20/2025 at a VWAP of $29.18 per share under a Rule 10b5-1 plan.

Q: Was the sale preplanned under a 10b5-1 plan?

Yes. The Form 4 states the sale was effected automatically pursuant to a Rule 10b5-1 trading plan adopted May 21, 2025.

Q: How many shares does the reporting person own after the transaction?

66,270 shares beneficially owned following the reported transaction(s), which includes 529 ESPP shares .

Q: What price range was reported for the sale?

Volume-weighted average price $29.18 ; the reported intraday sales price range was $28.94 to $29.47 on 08/20/2025.

Q: Who signed the Form 4?

The Form 4 was signed by Tobin Schilke as attorney-in-fact on 08/21/2025.

[Form 4] Crinetics Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Insider sale by Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals (CRNX). On 08/20/2025 Ms. Pizzuti sold 6,492 shares of Crinetics common stock in open-market transactions at a volume-weighted average price of $29.18 per share, with the intraday price range $28.94 to $29.47. The sale was effected automatically under a Rule 10b5-1 trading plan adopted May 21, 2025.

Following the reported transactions she beneficially owned 66,270 shares, which includes 529 shares acquired under the companys Employee Stock Purchase Plan. The Form 4 was signed by an attorney-in-fact on 08/21/2025.

Positive

Sale executed under a Rule 10b5-1 trading plan, indicating preplanned compliance with insider trading policies
Complete disclosure of transaction details: date, VWAP ($29.18), intraday price range ($28.94-$29.47) and remaining beneficial ownership
Includes ESPP holdings (529 shares) in beneficial ownership disclosure

Negative

Insider sale of 6,492 shares reduces the reporting person's stake
Form does not state exact breakdown of the number of shares sold at each price within the reported range (issuer offers details upon request)

Insights

TL;DR: Routine, prearranged insider sale under a 10b5-1 plan; transaction does not by itself indicate new company-specific adverse information.

The reported 6,492-share sale at a $29.18 VWAP was executed pursuant to a Rule 10b5-1 plan adopted May 21, 2025, which typically signals preplanned selling rather than opportunistic or informational trades. The remaining beneficial ownership is 66,270 shares, including 529 ESPP shares, as disclosed. From an investor disclosure perspective the filing is complete on key items: transaction date, volume, VWAP range and plan adoption date.

TL;DR: Governance controls appear operative: trade executed under documented 10b5-1 plan and form filed by attorney-in-fact.

The use of a documented Rule 10b5-1 trading plan provides an affirmative defense under insider trading rules and suggests the sale followed internal compliance procedures. The Form 4 includes necessary disclosures: reporting person identity, officer title, transaction details, and signature by an authorized attorney-in-fact. No amendments or additional material disclosures are present in the form.

08/21/2025 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pizzuti Dana

(Last)

(First)

(Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Med and Dev Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/20/2025		S⁽¹⁾		6,492	D	$29.18⁽²⁾	66,270⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025.

2. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $29.18 per share. The range of sales prices on the transaction date was $28.94 to $29.47 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

3. Includes 529 shares acquired under the Issuer's Employee Stock Purchase Plan.

	/s/ Tobin Schilke, as attorney-in-fact	08/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did Dana Pizzuti (CRNX) report on Form 4?

She reported selling 6,492 shares of Crinetics common stock on 08/20/2025 at a VWAP of $29.18 per share under a Rule 10b5-1 plan.

Was the sale preplanned under a 10b5-1 plan?

Yes. The Form 4 states the sale was effected automatically pursuant to a Rule 10b5-1 trading plan adopted May 21, 2025.

How many shares does the reporting person own after the transaction?

66,270 shares beneficially owned following the reported transaction(s), which includes 529 ESPP shares.

What price range was reported for the sale?

Volume-weighted average price $29.18; the reported intraday sales price range was $28.94 to $29.47 on 08/20/2025.

Who signed the Form 4?

The Form 4 was signed by Tobin Schilke as attorney-in-fact on 08/21/2025.

AG真人官方

[Form 4] Crinetics Pharmaceuticals, Inc. Insider Trading Activity

Insights

FAQ

What did Dana Pizzuti (CRNX) report on Form 4?

Was the sale preplanned under a 10b5-1 plan?

How many shares does the reporting person own after the transaction?

What price range was reported for the sale?

Who signed the Form 4?

NASDAQ:CRNX

CRNX Rankings

CRNX Latest News

CRNX Latest SEC Filings

CRNX Stock Data

AG真人官方

Trending News

[Form 4] Crinetics Pharmaceuticals, Inc. Insider Trading Activity

Insights

Securities Analyst neutral

Corporate Governance Expert neutral

FAQ

What did Dana Pizzuti (CRNX) report on Form 4?

Was the sale preplanned under a 10b5-1 plan?

How many shares does the reporting person own after the transaction?

What price range was reported for the sale?

Who signed the Form 4?

NASDAQ:CRNX

CRNX Rankings

CRNX Latest News

CRNX Latest SEC Filings

CRNX Stock Data